cx 5461 drug | CX-5461 Treatment Leads to Cytosolic DNA-Mediated STING

Keyword	CPC	PCC	Volume	Score	Length of keyword
cx 5461 drug	1.49	0.5	7345	30	12
cx	1.47	0.6	8576	13	2
5461	1.26	1	4449	15	4
drug	1.68	0.4	6186	92	4

Keyword	CPC	PCC	Volume	Score
cx-5461 drug	1.91	0.9	55	41
cx-5461 sigma	0.99	0.7	4014	67
cx-5461 solubility	1.84	1	301	84

Search Results related to cx 5461 drug on Search Engine

CX-5461 Treatment Leads to Cytosolic DNA-Mediated STING Acti…
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533980/

DA: 13 PA: 90 MOZ Rank: 22

CX-5461 activates the DNA damage response and demonstrates ... - Nature
nature.com

https://www.nature.com/articles/s41467-020-16393-4

DA: 37 PA: 9 MOZ Rank: 27

CX-5461 activates the DNA damage response and demonstrates …
nature.com

https://www.nature.com/articles/s41467-020-16393-4

WEBMay 26, 2020 · We propose CX-5461 is a promising therapy in combination with PARPi in HR-deficient HGSOC and also as a single agent for the treatment of relapsed disease. Author: Elaine Sanij, Elaine Sanij, Katherine M. Hannan, Katherine M. Hannan, Jiachen Xuan, Jiachen Xuan, Sh... Publish Year: 2020

Author: Elaine Sanij, Elaine Sanij, Katherine M. Hannan, Katherine M. Hannan, Jiachen Xuan, Jiachen Xuan, Sh...
Publish Year: 2020

DA: 95 PA: 90 MOZ Rank: 96

The chemotherapeutic drug CX-5461 is a potent mutagen in …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10786719/

WEBThe chemotherapeutic agent CX-5461, or pidnarulex, has been fast-tracked by the United States Food and Drug Administration for early-stage clinical studies of BRCA1-, BRCA2- …

DA: 2 PA: 22 MOZ Rank: 18

The chemotherapeutic agent CX-5461 irreversibly blocks RNA …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646227/

WEBNov 6, 2020 · CX-5461 is a potential inhibitor of ribosomal RNA synthesis that is now showing promise in phase I trials as a chemotherapeutic agent for a range of … Author: Jean-Clément Mars, Michel G Tremblay, Mélissa Valere, Dany S Sibai, Marianne Sabourin-Felix, Frédéri... DOI: 10.1093/narcan/zcaa032 Publish Year: 2020 Publication: NAR Cancer. 2020 Dec; 2(4): zcaa032.

Author: Jean-Clément Mars, Michel G Tremblay, Mélissa Valere, Dany S Sibai, Marianne Sabourin-Felix, Frédéri...
DOI: 10.1093/narcan/zcaa032
Publish Year: 2020
Publication: NAR Cancer. 2020 Dec; 2(4): zcaa032.

DA: 13 PA: 27 MOZ Rank: 71

OZM-114: Phase Ib expansion study of CX-5461in patients with …
ascopubs.org

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.TPS5621

WEBThe primary outcomes include assessment of: 1) Safety and tolerability of CX-5461, in particular to determine late onset ocular toxicity 2) Anti-tumor activity of CX-5461 in …

DA: 28 PA: 2 MOZ Rank: 72

CX-5461 Treatment Leads to Cytosolic DNA-Mediated STING …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533980/

WEBOct 9, 2021 · CX-5461 is an RNA polymerase I inhibitor that is in clinical trials for both advanced hematological cancers and solid tumors. Experimentally, this drug has been …

DA: 36 PA: 99 MOZ Rank: 59

Discovery of CX-5461, the First Direct and Selective …
acs.org

https://pubs.acs.org/doi/10.1021/ml300110s

WEBDiscovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics | ACS Medicinal Chemistry Letters. RETURN TO ISSUE PREV Letter. Discovery of CX-5461, the First …

DA: 2 PA: 30 MOZ Rank: 2

First-in-Human RNA Polymerase I Transcription Inhibitor CX …
aacrjournals.org

https://aacrjournals.org/cancerdiscovery/article/9/8/1036/41936/First-in-Human-RNA-Polymerase-I-Transcription

WEBAug 1, 2019 · CX-5461 induced rapid on-target inhibition of rDNA transcription, with p53 activation detected in tumor cells from one patient achieving a clinical response. One …

DA: 77 PA: 43 MOZ Rank: 79